ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
F star Therapeutics Inc

F star Therapeutics Inc (FSTX)

7.12
0.00
(0.00%)
At close: December 08 4:00PM
7.12
0.00
( 0.00% )

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
7.12
Bid
7.20
Ask
7.72
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
7.12
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

FSTX Latest News

F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3

Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022...

F-star Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

F-star Therapeutics to Host Virtual R&D Day on December 6, 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference

Dr. Michelle Morrow to present on F-star’s Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star’s...

F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) --  F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage...

F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...

F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
UPCUniverse Pharmaceuticals Inc
$ 3.38
(221.90%)
93.07M
LIFWMSP Recovery Inc
$ 3.2461
(104.16%)
29.08M
GXAIGaxos ai Inc
$ 2.5801
(81.70%)
145.87M
SBETSharpLink Gaming Inc
$ 0.9116
(73.97%)
27.08M
HCTIHealthcare Triangle Inc
$ 1.165
(68.38%)
4.34M
ORISOriental Rise Holdings Ltd
$ 3.6833
(-93.42%)
27.51M
LICNLichen China Limited
$ 0.4895
(-76.91%)
185.96M
MYNAMynaric AG
$ 0.499246
(-64.59%)
3.6M
CEROCERo Therapeutics Holdings Inc
$ 0.1146
(-40.16%)
37.87M
BTCTBTC Digital Ltd
$ 10.50
(-32.95%)
3.26M
SMXSMX Security Matters Public Company
$ 0.4879
(64.06%)
448.58M
SOUNSoundHound AI Inc
$ 15.01
(12.60%)
218.94M
NVDANVIDIA Corporation
$ 142.44
(-1.81%)
187.57M
LICNLichen China Limited
$ 0.4895
(-76.91%)
186.02M
SVMHSRIVARU Holding Ltd
$ 0.0293
(-16.29%)
162.46M

FSTX Discussion

View Posts
DK11 DK11 2 years ago
https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
And last one I hope. Lol....
👍️0
DK11 DK11 2 years ago
https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
Here is more information on this.
👍️0
DK11 DK11 2 years ago
https://www.sec.gov/Archives/edgar/data/1566373/000119312522309500/d439272d8k.htm
Looks like good news to me
👍️0
subslover subslover 2 years ago
invoX Pharma to Acquire F-Star Therapeutics (FSTX) for $7.12 Per Share
https://www.streetinsider.com/Corporate+News/invoX+Pharma+to+Acquire+F-Star+Therapeutics+%28FSTX%29+for+%247.12+Per+Share/20245945.html
👍️0
rhopton rhopton 3 years ago
someone has been hitting the sell button for 5 days straight, this is getting ridiculous that it can't move on major news like that, but these other stocks move 2 to 3 hundred percent on nothing
👍️0
maximumgriff maximumgriff 3 years ago
FJB!!!
👍️0
Docstemcell2020 Docstemcell2020 3 years ago
Let's go Brandon! FJB
👍️0
maximumgriff maximumgriff 3 years ago
Kinda crazy this hasn’t taken off with this mega license deal
👍️0
maximumgriff maximumgriff 3 years ago
Big news
👍️0
crudeoil24 crudeoil24 3 years ago
F-star Therapeutics Reports License Deal With J&J's Janssen To Develop, Commercialize Multiple Next Gen Bispecific Antibody Therapeutics; Co. To Receive Upfront Fees Of $17.5M, Near-Term Fees, Milestones Up To $1.35B
8:04 am ET October 20, 2021 (Benzinga) Print
F-star Therapeutics, Ltd. (NASDAQ:FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.

Under the terms of the agreement, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ and mAb2™ platforms. Janssen will be responsible for all research, development, and commercialization activities under the agreement.

Neil Brewis, Ph.D., Chief Scientific Officer of F-star said, “We are pleased to collaborate with Janssen and leverage the science of F-star’s proprietary tetravalent bispecific technology. Beyond our proprietary pipeline, we believe there is broad potential for our mAb2 platform to produce multiple next-generation bispecific antibody therapeutics.”

Under the terms of the agreement F-star is entitled to receive upfront fees of $17.5 million, near-term fees and potential further milestones of up to $1.35 billion. F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.
👍️0
Phosphene Phosphene 4 years ago
Form SC 13G F-star Therapeutics, Inc.

https://sec.report/Document/0001104659-21-010211/

Jasper Bos of Merck had been observer to BOD.

👍️0
Phosphene Phosphene 4 years ago
F-star pipeline includes partnered programs with Merck and Denali

Therapeutics.

https://www.f-star.com/pipeline/proprietary-pipeline/
👍️0

Your Recent History

Delayed Upgrade Clock